AP275A - Othomolecular method of treating sicle cell disease - Google Patents

Othomolecular method of treating sicle cell disease Download PDF

Info

Publication number
AP275A
AP275A APAP/P/1992/000358A AP9200358A AP275A AP 275 A AP275 A AP 275A AP 9200358 A AP9200358 A AP 9200358A AP 275 A AP275 A AP 275A
Authority
AP
ARIPO
Prior art keywords
pharmaceutical composition
vitamin
group
weight
agents
Prior art date
Application number
APAP/P/1992/000358A
Other languages
English (en)
Other versions
AP9200358A0 (en
Inventor
Michael Wilburn
Original Assignee
Zw
Michael Wilburn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zw, Michael Wilburn filed Critical Zw
Publication of AP9200358A0 publication Critical patent/AP9200358A0/xx
Application granted granted Critical
Publication of AP275A publication Critical patent/AP275A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
APAP/P/1992/000358A 1991-02-08 1992-01-27 Othomolecular method of treating sicle cell disease AP275A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/652,773 US5108754A (en) 1991-02-08 1991-02-08 Orthomolecular method of treating sickle cell disease

Publications (2)

Publication Number Publication Date
AP9200358A0 AP9200358A0 (en) 1992-04-30
AP275A true AP275A (en) 1993-07-18

Family

ID=24618098

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1992/000358A AP275A (en) 1991-02-08 1992-01-27 Othomolecular method of treating sicle cell disease

Country Status (15)

Country Link
US (1) US5108754A (ja)
EP (1) EP0571474B1 (ja)
JP (1) JPH06507382A (ja)
KR (1) KR100221118B1 (ja)
AP (1) AP275A (ja)
AT (1) ATE175204T1 (ja)
AU (1) AU662124B2 (ja)
BR (1) BR9205609A (ja)
CA (1) CA2103580C (ja)
DE (1) DE69228054T2 (ja)
DK (1) DK0571474T3 (ja)
ES (1) ES2125887T3 (ja)
GR (1) GR3029742T3 (ja)
IL (1) IL100663A (ja)
WO (1) WO1992013522A1 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
HUT72422A (en) * 1994-04-20 1996-04-29 Beres Export Import Rt Aquous concentrate and process for its preparation
US5626884A (en) * 1995-08-18 1997-05-06 Lockett; Curtis G. Treatment of sickle cell disease
US5693671A (en) * 1996-05-01 1997-12-02 Harbor-Ucla Research And Education Institute L-glutamine therapy for sickle cell diseases and thalassemia
US20080153761A1 (en) * 1998-04-08 2008-06-26 Theoharides Theoharis C Compositions for protection against superficial vasodilator flush syndrome, and methods of use
DE10062401A1 (de) * 2000-12-14 2002-06-20 Beiersdorf Ag Verwendung von Folsäure und/oder deren Derivaten zur Herstellung kosmetischer oder dermatologischer Zubereitungen zur Prophylaxe von Schäden an der hauteigenen DNA und/oder zur Reparatur bereits eingetretener Schäden an der hauteigenen DNA
KR20020088498A (ko) * 2001-05-17 2002-11-29 (주)미토콘 에스-아데노실메티오닌을 유효성분으로 함유하는 인슐린저항증 개선용 조성물
DE10243234A1 (de) * 2002-09-17 2004-03-25 Phenion Gmbh & Co. Kg Tocopherylester
CA2536827C (en) * 2003-07-09 2014-09-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US7250445B1 (en) * 2005-01-14 2007-07-31 Ehrenpreis Eli D Anti-oxidant suppository for treating radiation proctopathy and other anorectal disorders
CA2710349A1 (en) * 2007-12-27 2009-07-09 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide -donating compounds and uses thereof
US8840950B2 (en) 2010-05-26 2014-09-23 Jacqueline M. Hibbert Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore
EP3186356B1 (en) * 2014-07-30 2022-02-16 Case Western Reserve University Biochips to diagnose hemoglobin disorders and monitor blood cells
US10071112B2 (en) 2014-10-08 2018-09-11 Epigenetics Pharma Llc Vitamin E-nucleoside prodrugs
WO2016196281A1 (en) * 2015-06-01 2016-12-08 Nanometics Llc Mtap inhibitors for the treatment of sickle cemtap disease
US10768166B2 (en) 2016-09-08 2020-09-08 Hemex Health, Inc. Diagnostics systems and methods
US10349589B2 (en) 2016-09-08 2019-07-16 Hemex Health, Inc. Diagnostics systems and methods
KR20190092778A (ko) 2018-01-31 2019-08-08 양원용 태양광을 이용한 기능성 전동식 농약분무기
WO2020264182A1 (en) 2019-06-25 2020-12-30 Hemex Health, Inc. Diagnostics systems and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL57609A (en) * 1979-06-21 1983-05-15 Yeda Res & Dev Pharmaceutical compositions for the treatment of sickle cell disease comprising p-nitrobenzyl esters or amides of aromatic or hydrophobic aminoacids
US4612194A (en) * 1984-02-15 1986-09-16 Roshdy Ismail Anti-rheumatic agents and their use
GB8606913D0 (en) * 1986-03-20 1986-04-23 Hider R C Treatment of sickle cell disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"American Journal of Clinical Nutrition", May 1980, pp. 968-971 *

Also Published As

Publication number Publication date
KR100221118B1 (ko) 1999-09-15
DK0571474T3 (da) 1999-08-30
EP0571474A1 (en) 1993-12-01
GR3029742T3 (en) 1999-06-30
ES2125887T3 (es) 1999-03-16
EP0571474B1 (en) 1998-12-30
CA2103580A1 (en) 1992-08-09
JPH06507382A (ja) 1994-08-25
DE69228054T2 (de) 1999-08-05
AP9200358A0 (en) 1992-04-30
EP0571474A4 (ja) 1994-02-09
AU1250592A (en) 1992-09-07
CA2103580C (en) 2002-11-26
BR9205609A (pt) 1994-07-26
DE69228054D1 (de) 1999-02-11
ATE175204T1 (de) 1999-01-15
IL100663A0 (en) 1992-09-06
IL100663A (en) 1995-10-31
WO1992013522A1 (en) 1992-08-20
AU662124B2 (en) 1995-08-24
US5108754A (en) 1992-04-28

Similar Documents

Publication Publication Date Title
AP275A (en) Othomolecular method of treating sicle cell disease
Rieder et al. Hemoglobin Zürich: clinical, chemical and kinetic studies
Grinstein et al. Hemoglobin metabolism in thalassemia: in vivo studies
Alperin Coagulopathy caused by Vitamin K deficiency in critically III, hospitalized patients
Berk et al. Hematologic and biochemical studies in a case of lead poisoning
JP2008133290A (ja) リウマチ疾患の治療のための組合せ医薬製剤の製造のためのエリトロポイエチン製剤と鉄分製剤との使用
Wranne Transient erythroblastopenia in infancy and childhood
Bank et al. Absolute rates of globin chain synthesis in thalassemia
Özsoylu Homozygous hemoglobin D Punjab
Koup et al. Chloramphenicol pharmacokinetics in hospitalized patients
Koler et al. Hemoglobin casper: β 106 (G8) Leu→ Pro: A contemporary mutation
US5177208A (en) Orthomolecular method of treating sickle cell disease
Coburn et al. Granulomatous sarcoid nephritis
Kan et al. Equal synthesis of α-and β-globin chains in erythroid precursors in heterozygous β-thalassemia
Parfitt Familial neonatal hypoproteinaemia with exudative enteropathy and intestinal lymphangiectasis.
Savage et al. Idiopathic rhabdomyolysis
Snyder et al. G-6-PD Worcester: a new variant, associated with X-linked optic atrophy
Runckel et al. Effect of dimethyl sulfoxide on serum osmolality.
Freedman et al. Sickle hemoglobin gelation—inhibition by tris (hydroxymethyl) aminomethane and sugars
NECHELES et al. Red cell pyruvate kinase deficiency: The effect of splenectomy
Charache et al. Hemoglobin SC, SS/GPhiladelphia and SOArab diseases: Diagnostic importance of an integrative analysis of clinical, hematologic and electrophoretic findings
Wrigley et al. Progressive hereditary nephropathy: A variant of medullary cystic disease?
Kim et al. Inclusions in red blood cells containing Hb S or Hb C
Janakiraman et al. Hemolysis during BAL chelation therapy for high blood lead levels in two G6PD deficient children
Mengel et al. Development of hemolytic anemia in rats fed methionine